Spyre Therapeutics, Inc. (NASDAQ:SYRE) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$400M raised · US$85 a share · Jefferies +4 Dealers: Jefferies (co-lead), TD Cowen (co-lead), Leerink Partners (co-lead), Stifel (co-lead), LifeSci Capital Use of proceeds: To fund a pivotal program in hidradenitis suppurativa with SPY072, its TL1A monotherapy | Nov 3, 2026 |
| At-the-market programme of common stock Tranche closed: US$18M raised | Nov 3, 2026 |
| Public offering of common stock Made bigger: about US$403M · US$62 a share · Jefferies LLC +4 Dealers: Jefferies LLC (co-lead), Goldman Sachs & Co. LLC (co-lead), Evercore ISI (co-lead), Guggenheim Securities, LLC (co-lead), LifeSci Capital LLC | Apr 14, 2026 |
| Public offering of common stock Closed: US$316.2M raised · US$18.5 a share · Jefferies LLC +4 Dealers: Jefferies LLC (co-lead), TD Securities (USA) LLC (co-lead), Leerink Partners LLC (co-lead), Stifel, Nicolaus & Company, Incorporated (co-lead), Wedbush Securities Inc. | Oct 15, 2025 |